GHK-Cu Peptide: Complete Research Profile and Molecular Analysis

GHK-Cu was first identified in 1973 by Dr. Loren Pickart during research at the University of California, San Francisco. Pickart observed that albumin isolated from young human plasma (age 20–25) stimulated hepatocyte proliferation in culture, while albumin from older donors (age 60–80) lacked this activity. Subsequent fractionation identified the active component as a tripeptide with the sequence glycyl-L-histidyl-L-lysine, which forms a high-affinity complex with copper(II) ions.

The discovery of GHK-Cu emerged from comparative aging research and has since become one of the most extensively characterized bioactive peptides in the literature. Over five decades of investigation have produced a substantial body of evidence regarding its molecular interactions, gene regulatory effects, and potential applications across multiple research domains including wound biology, dermatology, and regenerative medicine.

GHK-Cu has a molecular weight of approximately 401.9 Da and is registered under CAS number 89030-95-5. The tripeptide binds copper(II) with a dissociation constant that favors complex formation at physiological pH, with the histidine imidazole nitrogen and the amino terminal nitrogen serving as primary coordination sites. The copper ion adopts a square-planar geometry within the peptide complex, a configuration that is critical for its biological activity.

• Molecular formula: C₁₄H₂₄CuN₆O₄
• Molecular weight: ~401.9 Da
• CAS number: 89030-95-5
• Copper coordination: Square-planar geometry via His imidazole N, terminal amine N, and two deprotonated amide N atoms
• Plasma concentration: Declines from ~200 ng/mL at age 20 to ~80 ng/mL by age 60
• Solubility: Freely soluble in aqueous media at physiological pH

The age-dependent decline in circulating GHK levels from approximately 200 ng/mL in young adults to 80 ng/mL by the sixth decade has been a central observation motivating research into the peptide's biological significance. This decline correlates temporally with reductions in tissue repair capacity, collagen synthesis rates, and antioxidant defense function observed during aging.

Genome-wide expression analyses conducted by Pickart and Margolina (2018) revealed that GHK-Cu modulates the expression of approximately 4,000 genes, representing 31.2% of the human genome assayed. This remarkably broad regulatory footprint encompasses genes involved in extracellular matrix remodeling, antioxidant defense, DNA repair, ubiquitin-proteasome pathways, and inflammatory signaling. The peptide upregulates genes associated with tissue repair while simultaneously suppressing genes linked to inflammation and fibrotic processes.

Among the most significant gene expression changes observed are upregulation of collagen synthesis genes (COL1A1, COL3A1), matrix metalloproteinase inhibitors (TIMPs), antioxidant enzymes (SOD, catalase), and DNA repair mediators. Conversely, GHK-Cu suppresses expression of pro-inflammatory cytokines including IL-6, TNF-alpha-related pathways, and several metalloproteinases associated with pathological tissue degradation. This bidirectional regulatory pattern is unusual for a small peptide and suggests interaction with upstream transcriptional regulators rather than direct gene-level effects.

GHK-Cu has been extensively studied in wound healing models spanning in vitro fibroblast cultures, organ culture systems, and animal models. Research by Pickart et al. (2015) documented that GHK-Cu-infused collagen dressings produced a 9-fold increase in wound collagen content compared to untreated controls. The peptide stimulates multiple phases of the wound repair cascade including inflammation resolution, fibroblast migration, angiogenesis, and matrix deposition.

Comparative studies have evaluated GHK-Cu against established reference compounds for collagen synthesis stimulation. GHK-Cu demonstrated approximately 70% improvement in collagen production metrics, compared to 50% for vitamin C and 40% for retinoic acid under equivalent experimental conditions. The peptide also promotes the synthesis of decorin, a small leucine-rich proteoglycan that regulates collagen fibrillogenesis and contributes to the structural organization of newly formed tissue.

The antioxidant properties of GHK-Cu operate through both direct and indirect mechanisms. Direct antioxidant activity includes the ability of the copper-peptide complex to quench reactive oxygen species and block copper(II)-dependent oxidation of low-density lipoprotein (LDL), a process implicated in oxidative tissue damage. In experimental systems, GHK-Cu effectively blocked Cu²⁺-dependent LDL oxidation, suggesting a protective role against metal-catalyzed free radical generation.

Indirect antioxidant effects are mediated through gene expression changes, particularly upregulation of superoxide dismutase (SOD), catalase, and glutathione-related enzymes. Research by Dou et al. (2020) published in Aging Pathobiology and Therapeutics further characterized the relationship between GHK-Cu and cellular oxidative stress responses, demonstrating enhanced resilience to oxidative challenge in GHK-Cu-treated cell populations. These dual mechanisms position GHK-Cu as a multifaceted modulator of oxidative homeostasis in research settings.

GHK-Cu is unique in that the tripeptide sequence Gly-His-Lys creates an exceptionally strong and specific copper(II) binding site via the histidine imidazole and the amino terminus. This high-affinity chelation (log K ~16.4) distinguishes it from other copper-binding peptides and enables controlled copper delivery in experimental systems.

Gene expression studies using microarray analysis have identified over 4,000 genes modulated by GHK-Cu in cell culture, including those involved in collagen synthesis (COL1A1, COL3A1), antioxidant defense (SOD, catalase), and tissue remodeling (MMPs, TIMPs). These findings are from in vitro research and require further validation.

Research-grade GHK-Cu typically requires ≥98% purity as determined by reversed-phase HPLC, with copper content verified by inductively coupled plasma mass spectrometry (ICP-MS). Identity is confirmed via electrospray ionization mass spectrometry (ESI-MS) with an expected [M+H]+ of 404.15 Da.

• Read more: Copper Peptide Research: GHK-Cu Science, Mechanisms, and Biological Activity → https://www.chemverify.com/learn/copper-peptide
• Read more: Cyclic Lipopeptides: Biosurfactant Peptides as Next-Generation Drug Delivery Modulators → https://www.chemverify.com/learn/cyclic-lipopeptides-drug-delivery-modulators
• Read more: AI-Driven Peptide Discovery: Machine Learning in Peptide Research → https://www.chemverify.com/learn/ai-peptide-discovery-2026
• Read more: GLP-1 Receptor Agonists Demonstrate Cardiorenal Protection in Chronic Kidney Disease: Meta-Analysis → https://www.chemverify.com/learn/glp1-receptor-agonists-cardiorenal-protection-ckd